MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Galectin Therapeutics Company Profile (NASDAQ:GALT)

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.00 (745.07% upside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetActions
3/28/2016HC WainwrightInitiated CoverageBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015FBR & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015MLV & Co.Reiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/1/2014AegisDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2014BMO Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 4/30/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha